A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]

Value in Health

Volumn 21, Issue 2, 2018, Pages 161-165

  Garrison, Louis P ^a   Neumann, Peter J ^b   Willke, Richard J ^c   Basu, Anirban ^a   Danzon, Patricia M ^d   Doshi, Jalpa A ^e   Drummond, Michael F ^f   Lakdawalla, Darius N ^g   Pauly, Mark V ^d   Phelps, Charles E ^h   Ramsey, Scott D ^a   Towse, Adrian ⁱ   Weinstein, Milton C ^j  

^a UNIVERSITY OF WASHINGTON   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c International Society for Pharmacoeconomics and Outcomes Research   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF YORK   (United Kingdom)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF ROCHESTER   (United States)

ⁱ Office of Health Economics   (United Kingdom)

^j HARVARD UNIVERSITY   (United States)

more..

Author keywords

augmented cost effectiveness analysis; benefit cost analysis; multi criteria decision analysis; value frameworks

Indexed keywords

ARTICLE; BUDGET; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; ADVISORY COMMITTEE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; OUTCOME ASSESSMENT; PHARMACOECONOMICS; PROCEDURES; UNITED STATES;

ADVISORY COMMITTEES; COST-BENEFIT ANALYSIS; DECISION MAKING; DELIVERY OF HEALTH CARE; ECONOMICS, PHARMACEUTICAL; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; INSURANCE, HEALTH; OUTCOME ASSESSMENT (HEALTH CARE); TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 85042334200     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2017.12.009     Document Type: Article

References (6)

1. Neumann, P.J., Willke, R.J., Garrison, L.P., A health economics approach to US value assessment frameworks—introduction: an ISPOR Special Task Force report [1]. Value Health 21 (2018), 119–123.
2. Garrison, L.P., Pauly, M.V., Willke, R.J., Neumann, P.J., An overview of value, perspective, and decision context—a health economics approach: an ISPOR Special Task Force report [2]. Value Health 21 (2018), 124–130.
3. Lakdawalla, D.N., Doshi, J.A., Garrison, L.P., Phelps, C.E., Basu, A., Danzon, P.M., Defining elements of value in health care—a health economics approach: an ISPOR Special Task Force report [3]. Value Health 21 (2018), 131–139.
4. Danzon, P.M., Drummond, M.F., Towse, A., Pauly, M.V., Objectives, budgets, thresholds, and opportunity costs—a health economics approach: an ISPOR Special Task Force report [4]. Value Health 21 (2018), 140–145.
5. Phelps, C.E., Lakdawalla, D.N., Basu, A., Drummond, M.F., Towse, A., Danzon, P.M., Approaches to aggregation and decision making—a health economics approach: an ISPOR Special Task Force report [5]. Value Health 21 (2018), 146–154.
6. Willke, R.J., Neumann, P.J., Garrison, L.P., Ramsey, S.D., Review of recent US value frameworks—a health economics approach: an ISPOR Special Task Force report [6]. Value Health 21 (2018), 155–160.